KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Current Assets (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Current Assets data on record, last reported at $4.2 billion in Q4 2025.

  • For Q4 2025, Current Assets fell 10.0% year-over-year to $4.2 billion; the TTM value through Dec 2025 reached $4.2 billion, down 10.0%, while the annual FY2025 figure was $4.2 billion, 10.0% down from the prior year.
  • Current Assets reached $4.2 billion in Q4 2025 per JAZZ's latest filing, up from $3.8 billion in the prior quarter.
  • Across five years, Current Assets topped out at $4.6 billion in Q4 2024 and bottomed at $2.5 billion in Q1 2022.
  • Average Current Assets over 5 years is $3.3 billion, with a median of $3.3 billion recorded in 2021.
  • Peak YoY movement for Current Assets: skyrocketed 108.67% in 2021, then fell 21.03% in 2022.
  • A 5-year view of Current Assets shows it stood at $2.6 billion in 2021, then decreased by 0.2% to $2.6 billion in 2022, then soared by 31.82% to $3.4 billion in 2023, then soared by 34.74% to $4.6 billion in 2024, then decreased by 10.0% to $4.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $4.2 billion in Q4 2025, $3.8 billion in Q3 2025, and $3.4 billion in Q2 2025.